logo-loader
Tissue Regenix Group PLC

Tissue Regenix Group - Hardman & Co: Full-year 2017 - what to look for

RNS Number : 0429H
Tissue Regenix Group PLC
08 March 2018
 

Hardman & Co: Full-year 2017 - what to look for

Full-year 2017: what to look for - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on expanding in the US wound care and orthopaedic markets: in August 2017, TRX acquired CellRight Technologies, providing synergistic bone regeneration technology. Full-year 2017 results will be the first to reflect the acquisition and will include five months of the enlarged entity. Sales from all three business segments are forecast to be strong (total £5.15m). We set out our underlying growth expectations below.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/08.03.18-full-year-2017-what-to-look-for.pdf

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622

 

mh@hardmanandco.com
dmh@hardmanandco.com
gp@hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKMGGFNNGGRZM
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix unveils growth strategy and positive EBITDA milestone

Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke discussed the company's 2023 operational and financial performance in an interview with Proactive's Stephen Gunnion. Tissue Regenix is a global leader in regenerative medicine, focusing on tissue-based scaffold technologies...

1 week, 2 days ago

2 min read